Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • Sangamo Therapeutics' Other Working Capital Changes rose 5522.44% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 31443.85%. This contributed to the annual value of $13.4 million for FY2024, which is 10833.35% up from last year.
  • As of Q3 2025, Sangamo Therapeutics' Other Working Capital Changes stood at -$1.3 million, which was up 5522.44% from -$4.9 million recorded in Q2 2025.
  • Sangamo Therapeutics' Other Working Capital Changes' 5-year high stood at $19.2 million during Q4 2024, with a 5-year trough of -$149.8 million in Q1 2023.
  • Over the past 5 years, Sangamo Therapeutics' median Other Working Capital Changes value was -$5.4 million (recorded in 2023), while the average stood at -$17.2 million.
  • Per our database at Business Quant, Sangamo Therapeutics' Other Working Capital Changes plummeted by 61303.56% in 2023 and then surged by 139548.82% in 2024.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Other Working Capital Changes stood at -$21.9 million in 2021, then fell by 20.38% to -$26.4 million in 2022, then surged by 94.37% to -$1.5 million in 2023, then skyrocketed by 1395.49% to $19.2 million in 2024, then crashed by 106.95% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$4.9 million for Q2 2025, and $2.6 million during Q1 2025.